Scientific Ind Stock Price, News & Analysis

Scientific Industries (OTCQB: SCND) reported Q1 FY2025 financial results with mixed performance. The company's Benchtop Lab Equipment Operations saw a 5% revenue increase to $2.3 million, while total net revenues decreased 3.1% to $2.4 million compared to Q1 FY2024. The company's net loss improved to $1.78 million ($(0.16) per share) from $2.05 million ($(0.20) per share) year-over-year. Notable achievements include securing $1.5 million in equity financing, receiving first peer-reviewed validation of DOTS MPS Platform, and beginning shipments of VIVID WORKSTATION. International sales declined 32.5% to $577,200, while gross margin slightly improved to 42.2%. The company's cash position stood at $1.3 million as of March 31, 2025.

Scientific Industries (OTCQB: SCND), a life sciences tool provider, will release its first quarter fiscal year 2025 financial results for the period ended March 31, 2025. The company will file Form 10Q and issue a press release after market close on May 13, 2025, followed by a conference call on May 14, 2025, at 11:00 AM Eastern Time.

Investors can participate by dialing (844) 481-2706 (domestic) or (412) 317-0662 (international). A webcast will be available on the company's Investor Relations page, with replay access through May 21, 2025. Scientific Industries specializes in laboratory equipment manufacturing, including the Vortex-Genie® 2 Mixer and Torbal® balances, and bioprocessing systems under the DOTS brand.

Scientific Industries (OTCQB: SCND) has secured $1.6 million in private placement funding to advance its SBI's DOTS Platform, a real-time bioprocessing system. The offering includes 1,550,000 shares of common stock at $1.00 per share, with each share including a warrant to purchase an additional share at $1.00 within six months.

The company plans to launch its first-in-class optical pH sensor and high-performance liquid injection system in the second half of 2025. The DOTS MPS platform aims to establish a new standard in parallel bioprocessing for AI and digital biology applications, providing affordable, structured, reliable, and repeatable data for shake flask research.

Brookline Capital Markets, a division of Arcadia Securities, , served as the exclusive placement agent for the offering.

Scientific Industries (OTCQB: SCND), a life sciences tool provider and developer of digitally simplified bioprocessing products, has announced its fiscal year 2024 financial results conference call scheduled for April 1, 2025, at 11:00 AM Eastern Time. The company filed its Form 10K and issued a press release on March 31, 2025, for the fiscal year ended December 31, 2024.

Investors can participate by dialing (844) 481-2706 (domestic) or (412) 317-0662 (international). A webcast will be available on the Company's Investor Relations page, with replay access through April 8, 2025. The company's subsidiary, Scientific Bioprocessing (SBI), specializes in bioprocess sensors, actuators, and data analytics software, offering solutions including the DOTS Platform that transforms standard shake flasks into smart mini bioreactors.

Scientific Industries (SCND) reported financial results for fiscal year 2024, showing mixed performance across divisions. The company's Bioprocessing Systems Operations achieved 24% revenue growth to $1.7M, driven by the newly launched DOTS MPS system. However, overall net revenues decreased 3.6% to $10.7M, with Benchtop Laboratory Equipment sales declining 7% to $9.0M.

The company significantly reduced operating expenses by 21% to $11.4M and cut total net losses by 29% to $6.4M ($0.61 per share). Gross profit was $4.7M with a 44.2% margin. The company maintained a strong financial position with $2.6M in cash and equivalents and $6.5M in working capital.

Key developments include the expansion of DOTS MPS into mammalian cell culture markets, launch of the VIVID WORKSTATION automated pill counter, and planned AI model integration. The company is currently conducting trials with six major pharma companies and plans to launch new products in 2025, including an optical pH sensor and liquid injection system.

Scientific Industries (SCND) reported Q3 2024 financial results with net revenues of $2.8M, up 7.1% YoY. The company's Bioprocessing Systems Operations showed three consecutive quarters of growth, with Q3 revenues up 6.6% to $452.5K. Gross margins improved 350 basis points to 49.2%. Operating expenses decreased by 23% to $2.6M, while net loss reduced by 46% to $1.18M. The company's DOTS MPS system was validated for mammalian cell culture use, and a new VIVID WORKSTATION targeting pharmacy chains is set to launch. Working capital stood at $8.0M as of September 30, 2024.

Scientific Industries (OTCQB: SCND) announced it will file Form 10Q on November 14, 2024, for its third quarter financial results ended September 30, 2024. The company will release Q3 2024 results before market open on November 15, 2024, followed by a conference call at 11:00 AM ET. The call will be accessible via phone at (844) 481-2706 or (412) 317-0662 (international) and through webcast on the company's Investor Relations page. A replay will be available until November 22, 2024.

Scientific Industries (OTCQB:SCND), a life sciences tool provider and developer of simplified bioprocessing products, will participate in the Craig-Hallum Bioprocessing Conference on September 19, 2024. John Nicols, Chairman of Scientific Bioprocessing (SBI), and John Moore, Chairman of the Company, will be featured in a fireside chat at 12:30 p.m. ET.

The conference will be held virtually, and a replay of the fireside chat will be available on the Company's investor website after the event. This presentation offers an opportunity for investors to gain insights into Scientific Industries' latest developments and strategies in the bioprocessing sector.

Scientific Industries (OTCQB:SCND) reported financial results for Q2 2024, ending June 30. Key highlights include:

- Net revenues: $2.6M (Q2) and $5.1M (H1), down 11.2% and 12.8% YoY respectively
- Gross profit margin: 48.8% (Q2), up 350 basis points YoY
- Operating expenses decreased by 26.5% (Q2) and 22% (H1) YoY
- Net loss reduced to $1.28M (Q2) and $3.34M (H1), improvements of 44% and 28% YoY
- Cash and investments totaled $3.9M with $8.6M working capital

The company saw strong pipeline growth for Bioprocessing DOTS MPS and Torbal VIVID products, with cost-saving initiatives significantly improving financial results.